We are analyzing https://link.springer.com/article/10.1007/s11883-018-0754-6.

Title:
Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis | Current Atherosclerosis Reports
Description:
Purpose The purpose of this review was to examine the role of IL-1β in the inflammatory process central to the development of atherosclerosis and to discuss current clinical evidence for treatments targeting IL-1β in coronary artery disease. Recent Findings IL-1β has been shown to modulate atherosclerotic plaque progression by upregulating the synthesis of adhesion molecules on endothelial cells, as well increasing activation and proliferation of vascular smooth muscle cells. Animal studies have further suggested that alterations in the balance between agonists and antagonists of IL-1β are important in promoting atherosclerosis. In humans, preliminary assessment of therapy targeting IL-1β noted early reductions in serum inflammatory biomarkers among those with systemic inflammatory or coronary artery disease. The CANTOS trial, a large randomized double-blind study found that canakinumab, a monoclonal antibody targeting IL-1β, reduced ischemic events in patients being treated for secondary prevention. Summary Cellular, animal, and now clinical studies have suggested a role for therapies aimed at IL-1β for treatment of CAD. However, given potential side effects and costs of these medications, further study is required to determine which patients may be most suited for treatment above current standard of care.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, google, scholar, cas, interleukin, atherosclerosis, ilβ, coronary, patients, receptor, antagonist, study, inflammation, disease, heart, cardiol, artery, examining, role, treatment, inflammatory, vascular, effects, circulation, trial, ilra, inhibition, mice, content, khan, targeting, canakinumab, gene, acute, myocardial, privacy, cookies, tardif, therapy, cantos, arteries, thromb, cell, gunn, apolipoprotein, infarction, abbate, anakinra, information, publish,

Topics {✒️}

jean-claude tardif declare nf-κb drives crosstalk month download article/chapter interleukin-1beta induces tissue treatments targeting il-1β platelet-derived growth factor c-reactive protein reduction cell type-specific expression atherosclerosis evidence-based medicine il-1ra gene polymorphism vcu-art2 pilot studies article google scholar mrc-ila heart study apolipoprotein e-deficient mice il-1β inhibition therapy e45641 meta-analysis suggesting serum il-1ra levels adverse cardiac remodeling interleukin-1 receptor antagonist interleukin-1-receptor antagonist vascular endothelial cells van tassell bw inflammatory process central interleukin-1 gene polymorphisms il-1 receptor antagonist anti-inflammatory therapy placebo-controlled trial privacy choices/manage cookies interleukin-1β decreases full article pdf anakinra improves vascular serum inflammatory biomarkers percutaneous coronary interventions acute myocardial infarction interleukin-1beta inhibition coronary artery disease vcu-art porcine coronary arteries american heart association hospital coronary events fatty-streak formation il-1β inhibitors il-1β inhibition anti-inflammatory therapies targeting interleukin-1 apoe-deficient mice stroke statistics subcommittee stroke statistics–2015 update coron artery dis eric rheaume

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis
         description:The purpose of this review was to examine the role of IL-1β in the inflammatory process central to the development of atherosclerosis and to discuss current clinical evidence for treatments targeting IL-1β in coronary artery disease. IL-1β has been shown to modulate atherosclerotic plaque progression by upregulating the synthesis of adhesion molecules on endothelial cells, as well increasing activation and proliferation of vascular smooth muscle cells. Animal studies have further suggested that alterations in the balance between agonists and antagonists of IL-1β are important in promoting atherosclerosis. In humans, preliminary assessment of therapy targeting IL-1β noted early reductions in serum inflammatory biomarkers among those with systemic inflammatory or coronary artery disease. The CANTOS trial, a large randomized double-blind study found that canakinumab, a monoclonal antibody targeting IL-1β, reduced ischemic events in patients being treated for secondary prevention. Cellular, animal, and now clinical studies have suggested a role for therapies aimed at IL-1β for treatment of CAD. However, given potential side effects and costs of these medications, further study is required to determine which patients may be most suited for treatment above current standard of care.
         datePublished:2018-09-15T00:00:00Z
         dateModified:2018-09-15T00:00:00Z
         pageStart:1
         pageEnd:8
         sameAs:https://doi.org/10.1007/s11883-018-0754-6
         keywords:
            Interleukin-1β
            Atherosclerosis
            Coronary artery disease
            Inflammation
            Angiology
            Cardiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11883-018-0754-6/MediaObjects/11883_2018_754_Fig1_HTML.png
         isPartOf:
            name:Current Atherosclerosis Reports
            issn:
               1534-6242
               1523-3804
            volumeNumber:20
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Razi Khan
               affiliation:
                     name:Royal Columbian Hospital
                     address:
                        name:Royal Columbian Hospital, New Westminster, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Eric Rheaume
               affiliation:
                     name:Montreal Heart Institute
                     address:
                        name:Montreal Heart Institute, Montreal, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jean-Claude Tardif
               affiliation:
                     name:Montreal Heart Institute
                     address:
                        name:Montreal Heart Institute, Montreal, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis
      description:The purpose of this review was to examine the role of IL-1β in the inflammatory process central to the development of atherosclerosis and to discuss current clinical evidence for treatments targeting IL-1β in coronary artery disease. IL-1β has been shown to modulate atherosclerotic plaque progression by upregulating the synthesis of adhesion molecules on endothelial cells, as well increasing activation and proliferation of vascular smooth muscle cells. Animal studies have further suggested that alterations in the balance between agonists and antagonists of IL-1β are important in promoting atherosclerosis. In humans, preliminary assessment of therapy targeting IL-1β noted early reductions in serum inflammatory biomarkers among those with systemic inflammatory or coronary artery disease. The CANTOS trial, a large randomized double-blind study found that canakinumab, a monoclonal antibody targeting IL-1β, reduced ischemic events in patients being treated for secondary prevention. Cellular, animal, and now clinical studies have suggested a role for therapies aimed at IL-1β for treatment of CAD. However, given potential side effects and costs of these medications, further study is required to determine which patients may be most suited for treatment above current standard of care.
      datePublished:2018-09-15T00:00:00Z
      dateModified:2018-09-15T00:00:00Z
      pageStart:1
      pageEnd:8
      sameAs:https://doi.org/10.1007/s11883-018-0754-6
      keywords:
         Interleukin-1β
         Atherosclerosis
         Coronary artery disease
         Inflammation
         Angiology
         Cardiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11883-018-0754-6/MediaObjects/11883_2018_754_Fig1_HTML.png
      isPartOf:
         name:Current Atherosclerosis Reports
         issn:
            1534-6242
            1523-3804
         volumeNumber:20
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Razi Khan
            affiliation:
                  name:Royal Columbian Hospital
                  address:
                     name:Royal Columbian Hospital, New Westminster, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Eric Rheaume
            affiliation:
                  name:Montreal Heart Institute
                  address:
                     name:Montreal Heart Institute, Montreal, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jean-Claude Tardif
            affiliation:
                  name:Montreal Heart Institute
                  address:
                     name:Montreal Heart Institute, Montreal, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Atherosclerosis Reports
      issn:
         1534-6242
         1523-3804
      volumeNumber:20
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Royal Columbian Hospital
      address:
         name:Royal Columbian Hospital, New Westminster, Canada
         type:PostalAddress
      name:Montreal Heart Institute
      address:
         name:Montreal Heart Institute, Montreal, Canada
         type:PostalAddress
      name:Montreal Heart Institute
      address:
         name:Montreal Heart Institute, Montreal, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Razi Khan
      affiliation:
            name:Royal Columbian Hospital
            address:
               name:Royal Columbian Hospital, New Westminster, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Eric Rheaume
      affiliation:
            name:Montreal Heart Institute
            address:
               name:Montreal Heart Institute, Montreal, Canada
               type:PostalAddress
            type:Organization
      name:Jean-Claude Tardif
      affiliation:
            name:Montreal Heart Institute
            address:
               name:Montreal Heart Institute, Montreal, Canada
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Royal Columbian Hospital, New Westminster, Canada
      name:Montreal Heart Institute, Montreal, Canada
      name:Montreal Heart Institute, Montreal, Canada
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(127)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.08s.

LINK . SPRINGER . COM {}